A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Trial Profile

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Jan 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2016, according to ClinicalTrials.gov record.
    • 14 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
    • 19 Nov 2015 Status changed from withdrawn prior to enrolment to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top